Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References We remain disciplined and shareholder-focused in our capital allocation H1 2022 updates Investing in the business Returning to shareholders Investments in organic business USD 4.5bn R&D¹ USD 0.5bn capital investments Capital allocation Growing annual dividend in CHF USD 7.5bn paid out Value-creating bolt-ons USD 0.9bn 1. Core R&D actuals 2022 27 Investor Relations | Q2 2022 Results priorities Share buybacks USD 9.4bn to be executed USD 5.6bn completed of the USD 15bn 1 NOVARTIS | Reimagining Medicine

View entire presentation